半夏白术天麻汤化裁治疗痰湿壅盛证原发性高血压的临床效果

摘要
图/表
参考文献(19)
相关文章 (15)

全文: PDF (446 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的探讨半夏白术天麻汤化裁治疗痰湿壅盛证原发性高血压的临床效果。方法选取2019年6月至2021年3月黑龙江省中医药科学院心内科收治的90 例痰湿壅盛证原发性高血压患者作为研究对象，采用随机数字表法将其分为对照组和治疗组，每组各45 例。对照组患者予以口服硝苯地平控释片治疗，治疗组患者在对照组的基础上予以半夏白术天麻汤化裁治疗。治疗8 周后，比较两组患者的中医证候积分、中医疗效、收缩压、舒张压、血清一氧化氮（NO）、内皮素-1（ET-1）水平变化及不良反应发生情况。结果治疗后，治疗组患者的总有效率为86.67%，高于对照组的75.56%，差异有统计学意义（P＜0.05）。两组患者治疗后的中医证候评分低于治疗前，且治疗组患者治疗后的中医证候评分低于对照组，差异均有统计学意义（P＜0.05）。治疗后，两组患者的收缩压、舒张压水平均低于治疗前，且治疗组患者治疗后的收缩压、舒张压水平均低于对照组，差异有统计学意义（P＜0.05）。治疗后，两组患者的NO 水平高于治疗前，ET-1 水平低于治疗前，且治疗组患者治疗后的NO 水平高于对照组，ET-1水平低于对照组，差异有统计学意义（P＜0.05）。在治疗过程中，未出现明显的不良反应。结论对痰湿壅盛证原发性高血压患者予半夏白术天麻汤化裁治疗，可提高降压效果，改善头痛、头晕等中医临床症状，改善血管内皮功能，且安全有效，值得临床推广。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章

关键词 ：半夏白术天麻汤, 原发性高血压, 痰湿壅盛证, 临床效果, 安全性

Abstract：Objective To explore the clinical effect of Banxia Baizhu Tianma Decoction flexible modification in the treatment of essential hypertension with phlegm-dampness syndrome. Methods Ninety patients with essential hypertension diagnosed as phlegm-dampness syndrome treated in the Department of Cardiology Heilongjiang Academy of Chinese Medicine Sciences from June 2019 to March 2021 were selected as the research subjects，and they were divided into the treatment group and the control group by the random number table method，45 cases in each group. The patients in the control group were treated with oral Nifedipine Controlled-release Tablets，and in the treatment group，they were treated with Banxia Baizhu Tianma Decoction flexible modification on the basis of the control group. After 8 weeks of treatment，traditional Chinese medicine (TCM) syndrome score，TCM efficacy，systolic blood pressure，diastolic blood pressure，serum nitric oxide (NO)，endothelin-1 (ET-1) levels and incidence of adverse reactions were compared between the two groups. Results After treatment，the total effectiveness rate of the treatment group was 86.67%，which was higher than that in the control group accounting for 75.56%，the difference was statistically significant (P＜0.05). The TCM syndrome scores of patients in the two groups after treatment were lower than those before treatment，and the TCM syndrome scores of patients in the treatment group were lower than those in the control group after treatment，and the differences were statistically significant (P＜0.05). After treatment，the systolic and diastolic blood pressure levels of patients in the two groups were lower than those before treatment，and the systolic and diastolic blood pressure levels of the patients in the treatment group after treatment were lower than those in the control group，the differences were statistically significant (P＜0.05). After treatment，the NO levels of patients in the two groups were higher than those before treatment，and the ET-1 levels of patients in the two groups were lower than those before treatment，the NO level of the treatment group after treatment was higher than that in the control group，and the ET-1 level of the treatment group after treatment was lower than that in the control group，the differences were statistically significant (P＜0.05). During the treatment，no obvious adverse reactions occurred. Conclusion For patients with essential hypertension identified as phlegm-dampness syndrome，Banxia Baizhu Tianma Decoction flexible modification can improve blood pressure lowering，headache，dizziness and other TCM clinical symptoms，as well as vascular endothelial function. It is safe and effective，and is worthy of clinical promotion.

Key words： Banxia Baizhu Tianma Decoction Essential hypertension Phlegm-dampness syndrome Clinical effect Security

收稿日期: 2021-07-22

基金资助:黑龙江省整理、传承老中医药专家学术思想课题（C214-38）

引用本文:

代洪绪；翟文姬；项聿华. 半夏白术天麻汤化裁治疗痰湿壅盛证原发性高血压的临床效果[J]. 中国当代医药, 2022, 29(1): 141-144.
DAI Hongxu1 ZHAI Wenji2▲ XIANG Yuhua1. Clinical effect of Banxia Baizhu Tianma Decoction flexible modification in the treatment of essential hypertension with phlegm-dampness syndrome. 中国当代医药, 2022, 29(1): 141-144.

链接本文:

http://dangdaiyiyao.com/CN/ 或 http://dangdaiyiyao.com/CN/Y2022/V29/I1/141

[1]	中国高血压防治指南修订委员会.中国高血压防治指南（2018年修订版）[J].中国心血管杂志，2019，24（1）：24-56.
[2]	王继光.高血压团队发展：健康中国，健康血压——上海市高血压研究所[J].中华高血压杂志，2019，27（10）：995-997.
[3]	胡盛寿，高润霖，刘力生，等.《中国心血管病报告2018》概要[J].中国循环杂志，2019，34（3）：209-220.
[4]	刘慧卿，金凤表，张志敏，等.松龄血脉康胶囊联合盐酸贝尼地平对原发性高血压患者的临床疗效[J].中成药，2020，42（12）：3180-3184.
[5]	俞巧，王恒和.近10年我国不同地域原发性高血压证型分布及中药应用规律分析[J].山东中医杂志，2020，39（1）：39-43，59.
[6]	刘力生.中国高血压防治指南2010[J].中华高血压杂志，2011，19（8）：701-743.
[7]	郑筱萸.中药新药临床研宄指导原则（试行）[M].北京：中国医药科技出版社，2002：73-77.
[8]	国家中医药管理局.中医病证诊断疗效标准[M].南京：南京大学出版社，1994：105-177.
[9]	邢志禹.新加半夏白术天麻汤治疗高血压病（痰瘀互结型）的临床观察[D].哈尔滨：黑龙江中医药大学，2020：23-24.
[10]	周蕾，蔡红芳.穴位埋线辅助治疗原发性高血压及对患者血管内皮功能的影响[J].中国针灸，2018，38（4）：349-352.
[11]	Davigon J，Ganz P.Role of endorthelial dysfunction in atherosclerosis[J].Circulation，2004，109（23）：377-379.
[12]	李京，张明雪，肖蕾，等.200 例高血压病患者中医体质与证候的相关性研究[J].中华中医药学刊，2018，36（12）：2907-2910.
[13]	闫梦晗，李晓，姜月华.半夏白术天麻汤的临床应用及药理研究进展[J].中西医结合心脑血管病杂志，2020，18（14）：2265-2268.
[14]	张宇霞，杨雨民，周芸慧，等.半夏白术天麻汤对痰湿壅盛型高血压大鼠血清ET-1 及NO 含量的影响[J].内蒙古中医药，2018，37（6）：99-101.
[15]	王依明，王秋红.半夏的化学成分、药理作用及毒性研究进展[J].中国药房，2020，31（21）：2676-2682.
[16]	单雅蒙，王洋，徐贵成.天麻治疗高血压病研究进展[J].世界中医药，2017，12（12）：3182-3185.
[17]	崔鹤蓉，王睿林，郭文博，等.茯苓的化学成分、药理作用及临床应用研究进展[J].西北药学杂志，2019，34（5）：694-700.
[18]	王涵，杨娜，谭静，等.白术化学成分、药理作用及临床应用的研究进展[J].甘肃医药，2018，37（1）：23-26.
[19]	熊娅，方仪德，韩亚鹏，等.橘红素药理作用研究进展[J].中成药，2018，40（9）：2030-2033.